

| Catalog No. | HB651186 |
|---|---|
| Species reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Host species | Human |
| Isotype | IgG |
| Clone ID | GIGA-564 |
| Biological activity | GIGA-564 (0.001-100 ug/mL) exhibits extremely low activity in blocking the binding of CTLA-4 to CD80 and CD86 in ELISA assays [1]. GIGA-564 (5 mg/kg; i.p.; once every 3 days; 3 doses) induces a lower level of peripheral Treg proliferation than Ipilimumab () in hCTLA-4 KI mice bearing MC38 tumors [1]. GIGA-564 (0.3 mg/kg; i.p.; once every 3 days; 3 doses) exhibits excellent anti-tumor activity in hCTLA-4 KI mice bearing MC38 tumors [1]. GIGA-564 (30 mg/kg; i.p.; once every 3 days; 9 doses) induces less toxicity than Ipilimumab () in hCTLA-4 knock-in (KI) and hCTLA-4/hPD-1 double knock-in (KI) mice, as evidenced by lower liver enzyme levels, reduced colitis, and the absence of skin lesions at the tested dose [1]. |
| Expression system | Mammalian cells |
| Clonality | Monoclonal |
| Target | CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4 |
| Endotoxin level | Please contact the lab for this information. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P16410 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | GIGA-564, GIGA564, GIGA564 |
| Background | Cytotoxic T-lymphocyte protein 4 (CD152/CTLA4) is a ~24 kDa protein. Inhibitory receptor acting as a major negative regulator of T-cell responses. Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. CD152 is the therapeutic target of ipilimumab (Yervoy). 1. Schwartz, JC. et al. (2001) Nature 410, 604-8. PMID: 11279501 2. Stamper, CC. et al. (2001) Nature 410, 608-11. PMID: 11279502 3. Teft, WA. et al. (2006) Annual review of immunology 24, 65-97. PMID: 16551244 4. Linsley, PS. et al. (1991) The Journal of experimental medicine 174, 561-9. PMID: 1714933 5. Zheng, Y. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 1683-91. PMID: 18641304 6. Ramagopal, UA. et al. (2017) Proceedings of the National Academy of Sciences of the United States of America 114, E4223-E4232. PMID: 28484017 |
| References | 1. Stone E L, et al. GIGA-564, a third generation anti-CTLA-4 with minimal ability to block CTLA-4 binding to B7 ligands, has enhanced efficacy but reduced toxicity compared to ipilimumab in pre-clinical models//JOURNAL FOR IMMUNOTHERAPY OF CANCER. BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND: BMJ PUBLISHING GROUP, 2022, 10: A1443-A1443. [HB651186] |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Anti-Human CD152/CTLA4 (GIGA-564)




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com


+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский